Aug 12, 2020
MobileODT completed $4 million series round C
Jun 16, 2020
Identification of Alpelisib (BYL 719) as a Potential Treatment for Endometrial Cancers
Jun 16, 2020
Support for cervical cancer screening using Pap and HPV testing together continues to grow among health care providers and women
May 13, 2020
Global Ovarian Cancer Market Assessment 2019-2029 - Roche Will Continue to Dominate as the Single Largest Player with Approx. 31% of Total Market Revenue in 2029
May 12, 2020
INOVIO to Present at RBC Capital Markets Virtual Global Healthcare Conference
Apr 28, 2020
Geisinger study of blood test for cancer shows promising results
Apr 23, 2020
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers
Apr 20, 2020
Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse(TM) Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors
Mar 30, 2020
INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia
Mar 04, 2020
The World Market for Cervical Cancer Drugs, Forecast to 2030 - Insights Into Avastin, Bevacizumb, Blemocin, Blenoxane, and More
Mar 02, 2020
Inovio Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
Mar 02, 2020
Inovio Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
Feb 14, 2020
The global HPV testing market is expected to grow at a CAGR of over 12% during the period 2019-2025
Feb 13, 2020
2020-2025 Human Papillomavirus (HPV) Testing Industry Report - Roche, Qiagen, Hologic and Abbott are Dominating the Competition
Feb 13, 2020
Study Surveys Molecular Landscape of Endometrial Cancer
Feb 12, 2020
The Global Human Papillomavirus (HPV) Testing Market to Reach Revenues of Over $1 Billion During the Period 2020 -2025 - Market Research by Arizton
Feb 10, 2020
Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)
Feb 03, 2020
Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections
Jan 14, 2020
ASKA Pharmaceutical Co., Ltd. and KinoPharma, Inc. Enter into Option Agreement for Treatment of Cervical Dysplasia
Dec 17, 2019
Immix adds Biotech VC Mesa Verde to Investor Syndicate and Receives IRB Approval to Enroll Patients in Phase 1b/2a Cancer Study in the United States